Recent studies have shown that systemically administered anti-TNFα agents (infliximab and adalimumab) can pass from the serum into inflamed IBD mucosal tissue12,13 and can also pass through the intestinal mucosa into the gut lumen12,14. The gene discussed is TNF; the disease is inflammatory bowel disease.